PT1853232E - Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização - Google Patents

Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização Download PDF

Info

Publication number
PT1853232E
PT1853232E PT06708346T PT06708346T PT1853232E PT 1853232 E PT1853232 E PT 1853232E PT 06708346 T PT06708346 T PT 06708346T PT 06708346 T PT06708346 T PT 06708346T PT 1853232 E PT1853232 E PT 1853232E
Authority
PT
Portugal
Prior art keywords
methods
dosage forms
adn
crystalline form
stable crystalline
Prior art date
Application number
PT06708346T
Other languages
English (en)
Inventor
Irene Eijgendaal
Gerrit Klein
Maria J L Terhorst-Van Amstel
Klaas Zwier
Nico Bruins
Hendrikus T Rigter
Eric Gout
Caroline Boon
Michiel H De Vries
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of PT1853232E publication Critical patent/PT1853232E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT06708346T 2005-02-18 2006-02-17 Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização PT1853232E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65414905P 2005-02-18 2005-02-18

Publications (1)

Publication Number Publication Date
PT1853232E true PT1853232E (pt) 2009-11-12

Family

ID=36383746

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06708346T PT1853232E (pt) 2005-02-18 2006-02-17 Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização

Country Status (12)

Country Link
US (1) US7423040B2 (pt)
EP (1) EP1853232B1 (pt)
AT (1) ATE439831T1 (pt)
CA (1) CA2598407A1 (pt)
DE (1) DE602006008583D1 (pt)
DK (1) DK1853232T3 (pt)
ES (1) ES2331487T3 (pt)
HR (1) HRP20090569T1 (pt)
PL (1) PL1853232T3 (pt)
PT (1) PT1853232E (pt)
SI (1) SI1853232T1 (pt)
WO (1) WO2006087369A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20090068290A1 (en) * 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
BRPI0715445A2 (pt) * 2006-08-31 2014-05-13 Solvay Pharm Bv Uso de um composto de bifeprunox, e, kit de titulação
US20080132520A1 (en) * 2006-08-31 2008-06-05 Winsemius Antje A Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds
US20100119622A1 (en) * 2008-09-15 2010-05-13 Auspex Pharmaceuticals, Inc. 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
TR199801942T2 (xx) 1996-03-29 2000-08-21 Duphar International Research B.V. Piperazin ve piperidin bile�ikleri.
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
CA2310950C (en) 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
JP5081622B2 (ja) 2004-09-21 2012-11-28 山▲東緑▼叶制▲薬▼有限公司 ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
ES2318783T3 (es) 2005-08-22 2009-05-01 Solvay Pharmaceuticals B.V. N-oxidos como profarmacos de derivados de piperazina y piperadina.

Also Published As

Publication number Publication date
DE602006008583D1 (de) 2009-10-01
HRP20090569T1 (hr) 2009-11-30
US7423040B2 (en) 2008-09-09
CA2598407A1 (en) 2006-08-24
EP1853232A1 (en) 2007-11-14
US20060194812A1 (en) 2006-08-31
EP1853232B1 (en) 2009-08-19
DK1853232T3 (da) 2009-12-14
ATE439831T1 (de) 2009-09-15
SI1853232T1 (sl) 2010-01-29
PL1853232T3 (pl) 2010-01-29
WO2006087369A1 (en) 2006-08-24
ES2331487T3 (es) 2010-01-05

Similar Documents

Publication Publication Date Title
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW200633980A (en) Pyridones useful as inhibitors of kinases
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
TW200612892A (en) Novel compounds
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TNSN08140A1 (pt)
HK1138572A1 (en) Aminopyrimidines useful as inhibitors of protein kinases
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
ATE433966T1 (de) Methylendipiperidinderivate
TW200716204A (en) Pharmaceutical composition
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.